Healthcare M&A Update

Executive Summary

Healthcare M&A activity showed improvement in Q2 2026, with deal volume stabilizing as buyer confidence gradually returned. Strategic acquirers continued to lead activity, focusing on diagnostics, life sciences, and tech-enabled care, while financial sponsors selectively pursued scalable platforms in niche segments.²

“Healthcare M&A activity in Q2 reflects a measured reengagement of buyers as market clarity improves,” said Brad Scharfenberg, Vice President at PCE. “Transactions are increasingly concentrated in high-quality platforms with scalable growth, resilient margins, and strong strategic alignment.”

Valuation multiples remained disciplined but showed early signs of improvements, with continued emphasis on durable growth and defensible business models. Below, we highlight key transactions, geographic trends, and emerging themes shaping the Healthcare M&A landscape.²

Market Dynamics

Ongoing macroeconomic uncertainty and a cautious financing environment continued to influence Healthcare M&A in Q2 2026, though transaction volume showed stabilization relative to Q1 levels. Valuation multiples showed signs of improvement, as median TEV/Revenue increased to 3.5x—up from 3.2x in the prior year. EBITDA multiples also increased to 14.0x—significantly up from 12.0x a year ago. Buyers continued to prioritize assets with cost efficiency, reimbursement stability, and exposure to outpatient and home-based care—segments viewed as lower-risk within the evolving healthcare delivery landscape.³

Buyer Landscape

Strategic Acquirers: Strategic acquirers continued to lead Healthcare M&A activity in Q2 2026, focusing on capability expansion in high-growth therapeutic areas. Notably, Arlo Technologies’ acquisition of Perfuse Therapeutics for $2.5B highlights continued appetite for large-scale, pipeline-driven transactions, particularly as strategic buyers seek to diversify into adjacent biomedical platforms, offset near-term revenue concentration, and strengthen long-term growth through differentiated therapeutic assets. Strategic dealmaking remained concentrated in life sciences, diagnostics, and biopharma, with an emphasis on differentiated assets and late-stage pipelines.⁴

Financial Buyers: Financial sponsors remained selective in Q2 2026, maintaining a disciplined approach focused on platform scalability, recurring revenue, and operational efficiency. Private equity activity continued to center on mid-market add-ons and platform investments, particularly in healthcare services and technology-enabled care sectors, where sponsors can drive value through consolidation and operational improvement. This targeted deployment of capital reflects ongoing selectivity and a preference for defensible business models with clear cash flow visibility.⁴

Industry Comparison

Healthcare M&A volume remained below prior-year levels on an LTM basis through Q2 2026, though activity showed early signs of stabilization relative to Q1. The sector continues to outperform more cyclical industries in deal resilience, accounting for a meaningful share of total M&A activity, supported by its non-discretionary demand profile and long-term demographic tailwinds. Valuation multiples expanded, with TEV/EBITDA increasing to 14.0x and TEV/Revenue reaching 3.5x; however, buyers maintained disciplined underwriting standards despite sustained capital interest in the sector.

Geographic Expansion

Top U.S. States: California (146 deals), Florida (89), and Texas (67) remained the most active Healthcare M&A markets on a trailing basis through Q2 2026, supported by strong provider networks, favorable demographics, and concentrated innovation hubs. Massachusetts (60) and New York (54) also remained highly active, reflecting continued consolidation in large healthcare markets.  

Cross-Border Trends: Cross-border activity remained active in Q2 2026, with international buyers continuing to target U.S. healthcare assets to access innovation and pipeline development. Notably, Servier (France) completed its acquisition of Day One Biopharmaceuticals (U.S.) for approximately $2.5B, underscoring sustained foreign interest in U.S. oncology pipelines and the strategic appeal of commercially ready pediatric cancer assets as a platform for international expansion. 

Notable Transactions

Largest Transactions Closed

Other Financial Buyer Transactions Closed

Other Strategic Buyer Transactions Closed

Emerging Trends

Key trends shaping Healthcare M&A:

1. Gene & Cell Therapy Platforms
   Gene and cell therapy M&A accelerated through Q2 2026 as biopharma acquirers expanded beyond established CAR-T platforms to build next-generation modality capabilities. Buyers increasingly targeted companies with differentiated gene-editing technologies, vector manufacturing infrastructure, and pipelines in rare disease, oncology, and neurology, where potentially curative therapies continue to command strong strategic interest and premium valuations.
2. AI and Digital Health Integration
   AI and digital health continue to play a central role in Healthcare M&A in Q2 2026, with sustained activity in data infrastructure, AI-enabled diagnostics, and digital care delivery platforms. Buyers are increasingly prioritizing technology-driven assets to improve operational efficiency, enhance clinical workflows, and support patient engagement, reinforcing AI as a core investment thesis rather than an emerging theme.^{2 7}
3. Mental & Behavioral Health Consolidation
   Behavioral health remained one of the most active healthcare M&A subsectors in Q2 2026, driven by fragmented markets, growing demand, and limited provider capacity. Private equity sponsors continued platform-building strategies through add-on acquisitions to expand scale, geographic reach, and payor leverage, reinforcing the sector as a leading healthcare services investment theme.^{5 7}
4. Shift Toward Outpatient and Value-Based Care Models
   The shift toward outpatient care, home-based services, and value-based care models remains firmly in place in Q2 2026. Buyers continue to prioritize lower-cost, scalable care delivery models aligned with cost containment and population health initiatives, supporting ongoing consolidation across healthcare services.^{7 8}
5. Subsector Spotlight: Life Sciences & Biopharma
   Life science and biopharma remain a core driver of Healthcare M&A in Q2 2026, with transaction activity concentrated in late stage pipelines, specialty therapeutics, and next generation modalities. Biopharma M&A has reached approximately $106 billion across ~201 deals year to date in 2026, reflecting a strong rebound in activity and continued strategic urgency. Strategic buyers are actively pursuing targeted acquisitions to address patent cliffs and strengthen innovation pipelines, with a continued preference for differentiated science, proven biology, and scalable clinical platforms.⁵
6. Subsector Spotlight: Outpatient & Ambulatory Care Services
   Outpatient and ambulatory care continue to attract strong investor interest in Q2 2026, driven by cost efficiency, favorable reimbursement dynamics, and shifting patient preferences toward lower-cost care settings. Healthcare services M&A has remained concentrated in outpatient-oriented segments, which accounted for a significant portion of transactions, with ~231 deals and ~$20.8B in collective value in recent periods, reflecting continued consolidation across ambulatory surgery centers, specialty clinics, and home-based care platforms. Buyers continue to prioritize scalable, capital-light models aligned with value-based care and population health strategies.⁸

Outlook for Next Quarter

Opportunities: Improving market visibility and selective reengagement from both strategic and financial buyers are supporting a gradual pickup in healthcare M&A activity in Q2 2026. Investors continue to target high-quality assets in technology-enabled care, life sciences, and outpatient services, with capital increasingly flowing toward scalable platforms with strong margins and clear growth pathways.²

Risks: Macroeconomic uncertainty, reimbursement visibility, and regulatory oversight remain key headwinds in Q2 2026, continuing to influence deal pacing and valuation discipline. Ongoing policy changes and cost pressures across providers and payors are contributing to a more selective investment environment, with buyers remaining cautious on assets exposed to regulatory or reimbursement volatility.²

Predicted Activity: Healthcare M&A in Q2 2026 continues to be defined by precision over volume, with buyers prioritizing differentiated assets that offer durable cash flows, scalable operating models, and strong strategic alignment. Dealmaking remains focused on targeted acquisitions—particularly in AI-enabled platforms, specialty care, and biopharma pipelines—while underwriting standards emphasize execution risk, integration planning, and long-term value creation over headline valuation metrics.²

PCE Transactions

 

Served as advisor to Taylors Pharmacy on their acquisition by Revelation Pharma

Served as advisor to Physician Associates on their acquisition by Orlando Health

Served as advisor to HemaCare on a fairness opinion

Served as advisor to Rotech Healthcare, Inc. on a purchase price allocation

Served as advisor to Harbor Retirement Associates for credit facility to fund growth plans

Issued a fairness opinion related to the sale of Telligen to an ESOP

Contact Us

David Jasmund Orlando Office 407-621-2111 | Email me now READ MORE →

Jon Gogolak Orlando Office 407-621-2136 | Email me now READ MORE →

Bradley Scharfenberg Orlando Office 407-621-2156 | Email me now READ MORE →